Press releases
Filter by year
- Dec 20, 2021Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Sy…
- Nov 08, 2021Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTES…
- Oct 18, 2021Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
- Sep 13, 2021Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was…
- Sep 03, 2021Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bla…
- Aug 18, 2021Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bla…
- Aug 12, 2021Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer
- Jul 06, 2021Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
- Jun 29, 2021Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive…
- Apr 15, 2021Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Blad…
- Apr 12, 2021Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
- Feb 12, 2021Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
- Feb 11, 2021Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monito…